Global Information
회사소개 | 문의 | 비교리스트

광견병 : 파이프라인 리뷰

Rabies - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 219865
페이지 정보 영문 96 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


광견병 : 파이프라인 리뷰 Rabies - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 96 Pages

광견병은 감염된 동물의 타액으로부터 사람에게 옮겨지는 치사성 바이러스로, 일반적으로 동물에게 물려서 바이러스에 의해 감염됩니다. 신체 일부의 감각 소실, 근기능 소실, 연하장애, 흥분성, 발열, 경련 등의 증상이 있으며, 야생 생물과의 접촉, 백신 접종을 하지 않은 애완동물과의 접촉 등이 소인입니다.

세계의 광견병 치료제 파이프라인에 대해 분석했으며, 현재 개발 파이프라인의 상황 및 최신 동향, 약제 개요, 주요 기업 및 개발중인 제품의 리뷰 등을 정리하여 전해드립니다.

서론

  • 조사 범위

광견병 - 개요

광견병 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

광견병 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

광견병 치료제 개발에 참여하고 있는 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Celltrion Inc
  • Curevac AG
  • Humabs BioMed SA
  • Indian Immunologicals Ltd
  • Kamada Ltd
  • Molecular Targeting Technologies Inc
  • NanoViricides Inc
  • Novavax Inc
  • PaxVax Inc
  • Sanofi Pasteur SA
  • Synermore Biologics Co Ltd
  • Trellis Bioscience Inc
  • VBI Vaccines Inc
  • Zydus Cadila Healthcare Ltd

약제 개요

광견병 - 휴지중인 프로젝트

광견병 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Rabies, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Rabies - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
  • Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
  • Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Rabies - Pipeline by CPL Biologicals Pvt Ltd, H1 2020
  • Rabies - Pipeline by Curevac AG, H1 2020
  • Rabies - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Rabies - Pipeline by Humabs BioMed SA, H1 2020
  • Rabies - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., H1 2020
  • Rabies - Pipeline by Molecular Targeting Technologies Inc, H1 2020
  • Rabies - Pipeline by NanoViricides Inc, H1 2020
  • Rabies - Pipeline by Sanofi, H1 2020
  • Rabies - Pipeline by Shandong Yidu Biotechnology Co Ltd, H1 2020
  • Rabies - Pipeline by Shanghai Qingsai Biotechnology Co Ltd, H1 2020
  • Rabies - Pipeline by Synermore Biologics Co Ltd, H1 2020
  • Rabies - Pipeline by Trellis Bioscience Inc, H1 2020
  • Rabies - Pipeline by Univercells SA, H1 2020
  • Rabies - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Rabies - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Rabies, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2020, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 3, 5, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rabies - Overview
    • Rabies - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rabies - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rabies - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Cadila Healthcare Ltd
    • Changchun Bcht Biotechnology Co Ltd
    • Chengdu Rongsheng Pharmaceutical Co Ltd
    • Chongqing Zhifei Biological Products Co Ltd
    • CPL Biologicals Pvt Ltd
    • Curevac AG
    • GlaxoSmithKline Plc
    • Humabs BioMed SA
    • Indian Immunologicals Ltd
    • Mid-Atlantic BioTherapeutics, Inc.
    • Molecular Targeting Technologies Inc
    • NanoViricides Inc
    • Sanofi
    • Shandong Yidu Biotechnology Co Ltd
    • Shanghai Qingsai Biotechnology Co Ltd
    • Synermore Biologics Co Ltd
    • Trellis Bioscience Inc
    • Univercells SA
    • Yisheng Biopharma Co Ltd
  • Rabies - Drug Profiles
    • (Lassa fever + rabies) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-1014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNSP-333S1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-7202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-8102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3903133A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMT-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nadorameran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Niprab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RabiCide-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVC-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVC-58 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SO-57 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOJB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VerorabVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VRVg-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rabies - Dormant Projects
  • Rabies - Product Development Milestones
    • Featured News & Press Releases
      • Jan 07, 2020: CureVac announces positive results in low dose - 1 µg - Rabies vaccine clinical phase 1 study
      • Sep 03, 2019: Zydus to launch novel biologic for rabies, Twinrab
      • Jul 22, 2019: Yisheng Biopharma receives GMP certification from China NMPA for production of lyophilized rabies vaccine for preventive use
      • Oct 23, 2018: CureVac announces first study participant enrolled in Phase I clinical trial testing prophylactic mRNA
      • Oct 08, 2018: Yisheng Biopharma announces clearance from China FDA to proceed with PIKA rabies vaccine clinical study
      • Jul 26, 2017: CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine
      • Jun 30, 2017: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study
      • Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference
      • Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine
      • Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
      • Jul 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study
      • May 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study
      • Apr 30, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study
      • Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies
      • Mar 16, 2015: A new therapeutic vaccine successfully developed against rabies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q